EN DE
Watch SCM Lifescience Co. Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

SCM Lifescience Co. Ltd (298060) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of SCM Lifescience Co. Ltd stock KRW 976, price KRW 2,170, that is 55.0% below the price, quality 42 out of 100. Rating: strongly overvalued. Calculated from audited financials with 9 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR

SL SCM Lifescience Co. Ltd logo Thin data Nov 3, 2026

SCM Lifescience Co. Ltd

298060 · KQ
Very expensive, weak quality

Our calculation puts a fair price 55% below what the stock costs today.

Low debt
Revenue last quarter +18% vs. a year ago.
Quality 42/100
Expensive Growth (revenue 5y +136.8 %/yr in KRW)
Thin margins · 0.8% net margin (FY2025)
Fair value 976.36 KRW · Strongly overvalued
Negative free cash flow
Trails peers (3/10)
Narrow moat 13/100 · thin data
Thin data
Watch SCM Lifescience Co. Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

124,333 KRW 2,130 KRW Fair Value 976.36 KRW May 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.

How to read this chart

60‑month range 2,130 KRW – 124,333 KRW · fair‑value band 683.45 KRW – 1,269 KRW · the 2,170 KRW price screens above the 976.36 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 3, 2026.

Follow SCM Lifescience Co. in your weekly email

Every Wednesday you see whether SCM Lifescience Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

POONGJEON PHARMACY CO.,LTD. operates as a stem cell therapy company in South Korea.

Show moreShow less

It develops SCM-AGH, a treatment for moderate to severe acute pancreatitis and moderate to severe atopic dermatitis, as well as chronic graft versus host disease; and Iroro Deerscalp, a toothbrush cosmetic for hair loss relief.

The company was formerly known as SCM Lifescience Co., Ltd. and change its name to POONGJEON PHARMACY CO.,LTD. in April 2026. The company was incorporated in 2014 and is headquartered in Incheon, South Korea.

Stock analysis

SCM Lifescience Co. Ltd (298060) currently trades at 2,170 KRW, while our model-based Fair Value estimate is 976.36 KRW, 55% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Economic Profit group reads highest at a median of 2,318 KRW per share, and 2 of the 9 models we run sit above the 2,170 KRW price.

Bear case: the Multiples group reads lowest at 462.33 KRW, and 7 of the 9 models stay below the price. Data coverage for this calculation is low.

Scenario range: 683.45 KRW (bear) to 1,269 KRW (bull), the price of 2,170 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

SCM Lifescience Co. Ltd reported revenue of 23.8B KRW in FY2025 versus 439M KRW in FY2021, a compound +171.4%/yr. Reported net income was 203M KRW in FY2025.

Key figures

Market cap 20.2B KRW (≈ $14.9M) Micro · P/S ratio 14.3 · EPS (TTM) −854.88 KRW · Net margin 0.8% · Return on equity −41.9% · Return on assets (EBIT) −33.8% (5-year average) · Operating margin −8.2% · Revenue growth (YoY) +17.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 13 out of 100 (low confidence).

What moves the price

The share trades about 61% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −55%, 298060 screens richer than that median.

Fair Value models

Bear 683.45 KRW Fair Value 976.36 KRW Bull 1,269 KRW
Price 2,170 KRW · Downside -55.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income 2,218 KRW 2,318 KRW 2,525 KRW 68
Growth-Adj P/E 683.45 KRW 976.36 KRW 1,269 KRW 65
P/E Multiple 346.75 KRW 462.33 KRW 577.91 KRW 63
All 9 models by family
Earnings-Based
Graham-Dodd 142.90 KRW 996.58 KRW 1,399 KRW 61
Lynch FV 514.87 KRW 735.52 KRW 956.18 KRW 59
PEG = 1.0 514.87 KRW 735.52 KRW 956.18 KRW 55
Multiples
P/E Multiple 346.75 KRW 462.33 KRW 577.91 KRW 63
P/S Multiple 267.94 KRW 357.25 KRW 446.57 KRW 58
P/B Multiple 10,162 KRW 13,549 KRW 16,936 KRW 55
Asset-Based
NCAV (Graham) 978.46 KRW 1,483 KRW 1,853 KRW 54
Economic Profit
Residual Income 2,218 KRW 2,318 KRW 2,525 KRW 68
Growth Earnings
Growth-Adj P/E 683.45 KRW 976.36 KRW 1,269 KRW 65

Open the full fair value analysis →

Quality Score breakdown

Overall quality 42/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 19
How much profit the company makes from its sales and capital
Quality Growth 80
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 59
Debt, balance sheet and risk of trouble
Investment 17
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 11
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 100
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 52/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+2,790.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+291.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+136.8%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+130.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−5,016.8% (2020) → −19.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed

298060 screens overvalued: fair value 55% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare SCM Lifescience Co. Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 559 stocks

Beats the industry median on 3/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 42 · Below median
Fair Value upside −55.0% · Below median
Profitability
Return on assets 0.4% · Above median
Net margin (12 months) 0.8% · Below median
Operating margin (12 months) −8.2% · Below median
Growth and dividend
Revenue growth (quarter YoY) 17.8% · Above median
Balance sheet
Debt / equity 0.09× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.56× · Cheapest 25%
P/S (12 months) 13.07× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)89 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)96 · sector 97
DIVIDEND (yield)0 · sector 21

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs 298060
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs 298060
Samsung Biologics Co 207940 1,510,000 KRW 1,667,600 KRW +10% vs 298060
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs 298060
Genmab A/S GMAB kr 3,527 kr 3,880 +10% vs 298060
WuXi Biologics (Cayman) Inc 2269 HK$48.92 HK$52.38 +7% vs 298060
argenx SE ARGX $927.21 $908.40 −2% vs 298060
CSL Limited CSL A$200.77 A$183.04 −9% vs 298060
Celltrion, Inc 068270 210,000 KRW 74,945 KRW −64% vs 298060
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs 298060

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

SCM Lifescience Co. Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "SCM Lifescience Co. Ltd Fair Value". https://www.fairvalue-calculator.com/stock/298060

Frequently asked questions

Is SCM Lifescience Co. Ltd (298060) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of 976.36 KRW versus a price of 2,170 KRW, about 55% lower (overvalued).
What is the fair value of 298060?
Our model-based fair value for SCM Lifescience Co. Ltd is 976.36 KRW (as of Nov 3, 2026), built from audited fundamentals. The current price: 2,170 KRW.
What is the quality score of 298060?
SCM Lifescience Co. Ltd has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for SCM Lifescience Co. Ltd (298060)?
Our model-based price target is the fair value of 976.36 KRW (as of Nov 3, 2026) from 9 valuation models. Cautious scenario 683.45 KRW, optimistic scenario 1,269 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the SCM Lifescience Co. Ltd stock forecast for 2026?
Our models put fair value at 976.36 KRW, about 55% lower versus a price of 2,170 KRW (overvalued). Cautious scenario 683.45 KRW, optimistic scenario 1,269 KRW. The calculation is refreshed regularly with new filings.
What is the intrinsic value of SCM Lifescience Co. Ltd (298060)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For SCM Lifescience Co. Ltd it is 976.36 KRW per share (as of Nov 3, 2026), against a price of 2,170 KRW. It is the blended result of 9 valuation models in 5 families (Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is SCM Lifescience Co. Ltd stock overvalued or undervalued in 2026?
As of Nov 3, 2026, 298060 trades above its calculated fair value: price 2,170 KRW, fair value 976.36 KRW, a gap of about −55% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 298060?
No. The price is what the market pays today (2,170 KRW); the fair value is what the company's own numbers justify (976.36 KRW). For SCM Lifescience Co. Ltd the two are 1,194 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is SCM Lifescience Co. Ltd worth?
The market values SCM Lifescience Co. Ltd at about 20.2B KRW (market capitalisation, as of Nov 3, 2026). Per share that is 2,170 KRW; our models calculate a fair value of 976.36 KRW per share.
What do the bullish and bearish scenarios say about 298060?
Our models span a range for SCM Lifescience Co. Ltd: cautious scenario 683.45 KRW, base 976.36 KRW, optimistic 1,269 KRW per share (as of Nov 3, 2026, price 2,170 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of SCM Lifescience Co. Ltd (298060)?
Balance-sheet figures for SCM Lifescience Co. Ltd (as of Nov 3, 2026): return on equity −41.9%, debt of 0.09 per unit of equity. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is 298060 from its 52-week high?
SCM Lifescience Co. Ltd trades at 2,170 KRW, about 61% below its 52-week high of 5,615 KRW and 2% above the low of 2,130 KRW (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 976.36 KRW is for.
Which stocks are comparable to SCM Lifescience Co. Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is SCM Lifescience Co. Ltd stock attractive at the current price?
The data as of Nov 3, 2026: price 2,170 KRW, calculated fair value 976.36 KRW (−55%), Quality Score 42/100, from 9 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 298060 calculated?
We run SCM Lifescience Co. Ltd through 9 models from 5 families: Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 976.36 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. SCM Lifescience Co. Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of SCM Lifescience Co. Ltd (298060)?
The closing price on Nov 9, 2026 was 2,170 KRW. Our model-based fair value is 976.36 KRW, about 55% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with SCM Lifescience Co. Ltd right now?
The price sits above even our optimistic bull case (1,269 KRW). The favourable scenario is already priced in. Weak quality (42/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (683.45 KRW to 1,269 KRW) leaves room in how you read the outcome.

Key figures of SCM Lifescience Co. Ltd

How large is the market capitalisation of SCM Lifescience Co. Ltd (298060)?
The market capitalisation of SCM Lifescience Co. Ltd is 20.2B KRW (≈ $14.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of SCM Lifescience Co. Ltd (298060)?
The price-to-sales ratio of SCM Lifescience Co. Ltd is 14.3 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of SCM Lifescience Co. Ltd (298060)?
Earnings per share at SCM Lifescience Co. Ltd are −854.88 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of SCM Lifescience Co. Ltd (298060)?
The net margin of SCM Lifescience Co. Ltd is 0.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of SCM Lifescience Co. Ltd (298060)?
The return on equity (ROE) of SCM Lifescience Co. Ltd is −41.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of SCM Lifescience Co. Ltd (298060)?
On an EBIT basis the return on assets of SCM Lifescience Co. Ltd is −33.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of SCM Lifescience Co. Ltd (298060)?
The operating margin of SCM Lifescience Co. Ltd is −8.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at SCM Lifescience Co. Ltd (298060)?
Revenue at SCM Lifescience Co. Ltd is growing +17.8% versus a year earlier (3y avg +292%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does SCM Lifescience Co. Ltd (298060) generate?
The free cash flow of SCM Lifescience Co. Ltd is −10.0B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does SCM Lifescience Co. Ltd (298060) carry?
The net debt of SCM Lifescience Co. Ltd is 6.7B KRW (fiscal year 2024). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch SCM Lifescience Co. Ltd in the live analysis

One click puts SCM Lifescience Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.